Objective To investigate the therapeutic effect of meglumine adenosine cyclophosphate combined with isosorbide mononitrate for patients with chronic heart failure (CHF).
Methods A total of 92 CHF patients were selected as study subjects, and randomly divided into control group and study group, with 46 patients in each group.The control group was treated with meglumine adenosine cyclophosphate, and the study group was treated with isosorbide mononitrate on the basis of the control group.Clinical efficacy, left ventricular enddiastolic volume (LVEDV), left ventricular endsystolic volume (LVESV), left ventricular ejection fraction (LVEF), cardiac output (CO), N-terminal prohormone of brain natriuretic peptide (NT-proBNP), insulin growth factor-1(IGF-1), troponin T (cTnT) levels in two groups were observed.
Results The total effective rate in the study group was 95.65%, which was significantly higher than 76.09% in the control group (P < 0.05).After treatment, the levels of LVEDV, LVESV, NT-proBNP and cTnT in two groups were significantly lower than before treatment, and the study group was significantly lower than the control group (P < 0.05);the LVEF, CO and IGF-1 levels of two groups after treatment were significantly higher than before treatment, and the study group was significantly higher than the control group (P < 0.05).
Conclusion Meglumine adenosine cyclophosphate combined with isosorbide mononitrate in treatment of patients with CHF can effectively improve the cardiac function and clinical efficacy.
DownLoad: